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Serum Cytokine Profiling in Cats with Acute Idiopathic Cystitis
M. Parys , V. Yuzbasiyan-Gurkan, and J.M. Kruger
Background: Feline idiopathic cystitis (FIC) is a common lower urinary tract disorder of domestic cats that resembles
interstitial cystitis/painful bladder syndrome (IC/PBS) in humans. Diagnosis of FIC is based on clinical signs and exclusion
of other disorders because of a lack of specific pathologic findings or other objective biomarkers. Cytokines are potential
noninvasive biomarkers to define the presence, severity, and progression of disease, and response to treatment.
Objectives: The objective of this pilot study was to determine concentrations of selected cytokines in serum from healthy
cats and cats with acute FIC.
Animals: Serum samples from 13 healthy cats and from 12 cats with nonobstructive acute FIC were utilized.
Methods: Multiplex analysis of 19 cytokines (CCL2, CCL5, CXCL1, CXCL12, CXCL8, Flt3L, GM-CSF, IFN-c, IL-12
(p40), IL-13, IL-18, IL-1b, IL-2, IL-4, IL-6, PDGF-BB, SCF, sFas, and TNF-a) was performed with a commercially avail-
able feline-specific multiplex bead-based assay.
Results: Mean serum concentrations of IL-12 (p40; P < 0.0001), CXCL12 (P = 0.002), IL-18 (P = 0.032), and Flt3L
(P = 0.0024) were significantly increased in FIC cats compared to healthy cats. GM-CSF, IL-1b, IL-2, and PDGF-BB were
undetectable or detected in an insufficient number of cats to allow meaningful comparisons.
Conclusions and Clinical Importance: We have identified increased serum concentrations of pro-inflammatory cytokines
and chemokines CXCL12, IL-12, IL-18, and Flt3L in FIC-affected cats. These findings suggest potential candidates for non-
invasive biomarkers for diagnosis, staging, and therapeutic outcome monitoring of affected cats and provide additional
insight into the etiopathogenesis of FIC.
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Feline idiopathic cystitis (FIC) is the most commonlower urinary tract disorder in domestic cats and is
characterized by clinical signs of dysuria, pollakiuria,
periuria, stranguria, hematuria, and, in males, urinary
tract obstruction.1,2 The clinical and morphologic fea-
tures of FIC are strikingly similar to those of an idio-
pathic cystopathy of people called interstitial cystitis/
painful bladder syndrome (IC/PBS).1,2 As of yet, no
consistently reliable diagnostic markers establish a diag-
nosis of FIC or IC/PBS and differentiate among various
clinical and pathologic disease phenotypes.
Over the past several decades, a large number of poten-
tial serum and urine proteins that may be utilized as
biomarkers have been identified and evaluated in people
with IC/PBS.3,4 Similarly in cats with FIC, several urine
proteins have been found to be increased (C4a, NF-kB
p65, p38 MAPK, fibronectin, galectin-7, thioredoxin)5–8
or decreased (GP-51, I-FAB, trefoil factor 2)7–9 in urine of
affected cats compared to healthy controls. In contrast,
studies investigating serum biomarkers in cats with acute
or chronic FIC have not been performed to date. Because
FIC may be associated with factors that can induce sys-
temic immune activation and pro-inflammatory cytokine
release (eg, bladder inflammation, comorbid nonurinary
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Abbreviations:
CCL2 C-C motif chemokine ligand 2 (MCP-1)
CCL5 C-C motif chemokine ligand 5 (RANTES)
CXCL12 C-X-C motif chemokine ligand 12 (SDF-1)
CXCL1 C-X-C motif chemokine ligand 1 (KC)
CXCL8 C-X-C motif chemokine ligand 8 (IL-8—interleukin 8)
FeLV feline leukemia virus
FIC feline idiopathic cystitis
FIV feline immunodeficiency virus
Flt3L fms-related tyrosine kinase 3 ligand
GM-CSF granulocyte-macrophage colony-stimulating factor
IC/PBS interstitial cystitis/painful bladder syndrome
IFN-c interferon gamma
IL-12 (p40) interleukin 12 subunit p40
IL-13 interleukin 13
IL-18 interleukin 18





NSAIDs nonsteroidal anti-inflammatory drugs
PDGF-BB platelet-derived growth factor subunit B
SCF stem cell factor
sFas soluble Fas cell surface death receptor
TNF-a tumor necrosis factor alpha
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inflammatory conditions, and activation of sympathetic
nervous system),10–14 characterization of serum cytokine
and chemokine responses could offer additional insight
into the pathogenesis of FIC and identify potential nonin-
vasive biomarkers for diagnosis, prognosis, and prediction
of therapeutic responses. In 1 study of 22 nonobstructed
cats with chronic FIC, serum concentrations of trypto-
phan and its metabolite kynurenine were higher in FIC
cats compared to healthy controls, but differences did not
reach statistical significance.15
Inflammation appears to be involved in the pathogenesis
of some forms of FIC.12,13,16 Cytokines and chemokines
are factors important for migration, maturation, and pro-
liferation of immune cells and play key roles in host inflam-
matory and immune responses. In humans with IC/PBS,
cytokines and chemokines have been intensively studied as
potential serum or urine biomarkers of the disorder.11–13,16
Recently, a feline-specific bead-based multiplex assay has
become available for simultaneous detection of immuno-
logically active proteins in cats. Studies investigating the
analytical performance of the multiplex assay suggested
that at higher blood analyte concentrations, recovery was
linear and allowed for reliable cytokine detection in serum
or heparinized plasma samples.17 The objective of our
study was to investigate expression of 19 cytokines and
chemokines in serum of cats with untreated nonobstructive
acute FIC and in unaffected healthy control cats.
Materials and Methods
Study Population
In this retrospective pilot study, specimens included archived fro-
zen serum samples collected from 12 untreated cats with a clinical
diagnosis of nonobstructive acute FIC. All animals were evaluated
at Michigan State University Veterinary Medical Center. Control
samples were obtained from 13 clinically healthy client-owned,
blood donor or research colony cats. Acute FIC was diagnosed
based on clinical signs of dysuria, periuria, hematuria, or stranguria,
where other disease processes with similar clinical presentation had
been excluded. All cats were evaluated with a standardized medical
history, a complete physical examination, a complete urinalysis, a
urine culture, survey abdominal radiographs, and an abdominal
ultrasound examination to exclude other comorbidities. Addition-
ally, all FIC cats had serum biochemistry profiles, CBC, and FeLV/
FIV testing performed. Cats with acute FIC were excluded from the
study if they had another detectable disease process, had concurrent
urethral obstruction, or had been treated with antimicrobials, anti-
histamines, corticosteroids, nonsteroidal anti-inflammatory drugs
(NSAIDs), anticholinergics, antidepressants, urinary acidifiers, gly-
cosaminoglycans, diuretics, dimethyl sulfoxide, cyclophosphamide,
or any other medication used to treat IC/PBS.
Peripheral blood samples were obtained by venipuncture. Col-
lected samples were centrifuged at 2,000 g for 10 minutes. Serum
samples subsequently were cryopreserved at 80°C and remained
frozen until analysis.
All samples utilized in this study were obtained under informed
consent from the owners and with the approval of the Michigan
State University Institutional Animal Care and Use Committee.
Multiplex Cytokine Assays
A commercial feline-specific multiplex bead-based assaya was
utilized allowing for simultaneous measurement of 19 cytokines:
sFas, TNF-a, CXCL12, SCF, CCL5, PDGF-BB, CCL2, CXCL1,
IL-18, IL-13, IL-12 (p40), CXCL8, IL-6, IL-4, IL-2, IL-1b, IFN-c,
GM-CSF, and Flt3L.17 Serum samples were assayed according to
manufacturer’s recommendations. Sample analyte concentrations
were measured using a multiplexing platform,b and data were ana-
lyzed using a commercial analytical software package.c All assays
were run in duplicate.
Statistical Analysis
Statistical analysis was performed using commercially available
statistical software.d D’Agostino and Pearson omnibus test was
used to evaluate normality of data. Comparisons of cytokine con-
centrations between groups with normal distribution were per-
formed by Student t-test, otherwise the nonparametric Mann-
Whitney U test was performed.
Results
Animals
Samples from 12 FIC-affected cats (4 females and 8
males) and 13 healthy control cats (5 females and 8
males) were utilized in the study. Average age of
affected cats was 4 years, 11 months (SD  1 year,
10 months; range, 1 year, 5 months to 7 years), and
5 years, and 2 months (SD  1 year, 10 months; range,
1–7 years, 2 months) for control cats. All FIC cats had
clinical signs consistent with acute cystitis, with clinical
signs lasting an average of 3 days (SD  2.21 days;
range, 1–8 days) before presentation. The mean urine
specific gravity of FIC cats was significantly lower than
that of the control cats (P = 0.0081, t-test; FIC:
1.048  0.012 versus control 1.060  0.009). There
were no significant differences in urinary pH between
the groups (FIC: 6.6  0.53 versus control:
6.72  0.58). Struvite crystals were present in 3 affected
and 3 control cats. Bacterial culture was negative in all
animals. Microscopic hematuria was present in 9 FIC
cats and 2 controls. Pyuria was not observed in any
affected or control cat.
Some FIC cats had mild abnormalities in their blood
chemistry and CBC results including hyperglycemia (3/
12), increased CK activity (10/12), hypo- (1/12) or
hyper-natremia (1/12), hypochloremia (1/12), hypoglob-
ulinemia (1/12), hypocholesterolemia (2/12), hypofer-
ritinemia (2/12), increased TCO2 (1/12), increased AST
activity (2/12), increased ALT activity (1/12), hypophos-
phatemia (1/12), decreased hematocrit and hemoglobin
(2/12) as well as decreased RBC counts (1/12). All other
results were within reference ranges.
Serum Cytokine/Chemokine Concentration
Twelve FIC and 13 control serum samples were avail-
able for evaluation at the time of experiments. Four of
19 analytes were undetectable or detectable in an insuf-
ficient number of samples to make a meaningful com-
parison and were excluded from analyses. These
analytes were GM-CSF, IL-1b, IL-2, and PDGF-BB
(Table 1). Concentrations of 4 cytokines were signifi-
cantly increased in serum of FIC cats compared to con-
trols: IL-12 (p40) (P < 0.0001 Mann-Whitney test; FIC:
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median, 1,069; range, 551.3–2,042 pg/mL versus con-
trol: 1,221.8, 0–1,503 pg/mL), CXCL12 (SDF1)
(P = 0.002, Mann-Whitney test; FIC: 2,349; 0–3,523 pg/
mL versus control 0; 0–3,571 pg/mL), IL-18 (P = 0.032,
Mann-Whitney test; FIC: 379.8; 0–1,179 pg/mL versus
control: 0; 0–978.7 pg/mL), and Flt3L (P = 0.0024,
Mann-Whitney; FIC: 365.6; 219.7–563.8 pg/mL versus
control: 177; 112.7–1,215 pg/mL; Table 1, Fig 1).
Discussion
To our knowledge, ours is the first study investigating
serum concentrations of cytokines and chemokines in
cats with acute FIC. We have identified 4 cytokines that
were significantly higher in serum of FIC-affected cats
compared to healthy controls (IL-12 [p40], CXCL12,
IL-18, Flt3L). Studies investigating the expression of
these 4 cytokines in humans with IC/PBS have not been
reported. Although we did not detect significant differ-
ences in other serum cytokines in FIC cats compared to
controls, increased serum or plasma concentrations of
IL-1b, IL-6, CXCL8 (IL-8), and TNF-a have been
reported in people with IC/PBS compared to healthy
controls.18,19 Factors responsible for differences in cyto-
kine profiles between acute FIC and IC/PBS are
unknown, but may be related to differences in chronic-
ity of disease, pathophysiologic mechanisms, and ana-
lytical performance of cytokine assays. No studies have
investigated the expression of IL-2, IL-4, IL-12, IL-13,
IL-18, sFas, Flt3L, GM-CSF, IFN-c, CXCL1 (KC),
CXCL12 (SDF1), CCL2 (MCP-), CCL5 (RANTES),
PDGF-BB, and SCF in serum of people with IC/PBS.
Although comparative data on each cytokine is not
available for comparison of human IC/PBS and FIC
serum cytokine profiles, increased levels of circulating
pro-inflammatory cytokines are present in both
disorders.
Interleukin 12 is a pro-inflammatory cytokine com-
posed of 2 subunits: p35 and p40.20 Antigen-presenting
cells are the main source of IL-12 in the body, and IL-
12 is an important mediator of Th1 responses and
induction of INF-c production.20–22 Limited informa-
tion is available on the role of IL-12 in humans with
IC/PBS. This cytokine was not significantly increased in
bladder biopsies of human patients.23 However, urine
IL-12 was increased in human patients with overactive
bladder syndrome.24 Increased RNA expression of IL-
12 (p40) in bladder tissues also was identified in mice
with experimental autoimmune cystitis.25 Interestingly,
human patients receiving intravesicular instillation of
IL-12 for treatment of superficial bladder transitional
cell carcinoma had adverse effects that were similar to
IC/PBS such as pain, dysuria, or increased frequency.26
Identification of presence of IL-12 in urine of cats with
FIC warrants further investigation and will depend on
validation and optimization of assays for detection of
cytokines in feline urine.
Interleukin 18 is another Th1 pro-inflammatory cyto-
kine, and significantly increased serum concentrations
were observed in our cohort of FIC-affected patients.
Interleukin 18 was observed to be significantly increased
in bladder tissues of IC/PBS-affected human patients.23
Furthermore, decreasing urine concentrations of this
cytokine in patients with IC/PBS have correlated with
clinical improvement after hydrodistention therapy.23 It
is well established that IL-18 and IL-12 work in synergy
to induce INF-c expression in T-cells, NK cells, and
dendritic cells.22,27 Although in our study we did not
identify increased concentrations of INF-c in FIC
patients, previous studies have identified a potential
serum biomarker, kynurenine,15 which is produced by
an INF-c-inducible gene IDO1.28–30 Importantly, this
gene is known to be INF-c inducible in cats as well,30
so one can speculate that INF-c may be more locally
produced in FIC cats in early stage of the disease, and
furthermore, our findings of increased serum concentra-
tions of IL-12 and IL-18 suggest they may work in con-
junction with INF-c in FIC.
CXCL12 (also known as SDF1) is a chemokine,
which induces migration of various cells such as T-cells,
B-cells, macrophages, and dendritic cells which express
Table 1. Median and range of concentrations of 19
cytokine/chemokine measured in serum from 12 cats
with acute FIC and 13 healthy control cats. In bold are
cytokines significantly different between 2 groups.
Cytokine
Serum Concentration in pg/mL (Median, Range)
FIC (n = 12) Healthy (n = 13) P Value
sFas 0 (0–161.3) 0 (0–127.4) 0.38
Flt3L 365.6 (219.7–563.8) 177 (112.7–1,215) 0.0024
GM-CSF ND ND




IL-12 (p40) 1,069 (551.3–2,042) 121.8 (0–1,503) <0.0001
IL-13 27.02 (0–164.1) 45.05 (0–217.1) 0.66
IL-4 416.6 (89.35–1,734) 1,204 (72.35–3,598) 0.14
IL-6 0 (0–929.7) 260.6 (0–1,929) 0.33
CXCL8
(IL-8)
24.43 (0–148.4) 82.46 (0–673) 0.17
CXCL1
(KC)
48.04 (0–468.7) 13.18 (0–110.7) 0.11
CXCL12
(SDF1)
2,349 (0–3,523) 0 (0–3,571) 0.002
RANTES 113.8 (51.9–361.9) 96.4 (12.7–683.5) 0.27
SCF 219 (0–493.6) 223.9 (1.39–1,525) 0.73
MCP-1 0 (0–8,249) 4,214 (0–35,065) 0.18
TNF-a 0 (0–817) 60.4 (0–7,495) 0.4342
IL-18 379.8 (0–1,179) 0 (0–978.7) 0.032
CCL2, C-C motif chemokine ligand 2 (MCP-1); CCL5, C-C
motif chemokine ligand 5 (RANTES); CXCL1, C-X-C motif che-
mokine ligand 1 (KC); CXCL12, C-X-C motif chemokine ligand
12 (SDF-1); CXCL8, C-X-C motif chemokine ligand 8 (IL-8,
interleukin 8); Flt3L, fms-related tyrosine kinase 3 ligand; GM-
CSF, granulocyte-macrophage colony-stimulating factor; IFN-c,
interferon gamma; IL-12 (p40), interleukin 12 subunit p40; IL-13,
interleukin 13; IL-18, interleukin 18; IL-1b, interleukin 1 beta; IL-
2, interleukin 2; IL-4, interleukin 4; IL-6, interleukin 6; ND, not
detected; PDGF-BB, platelet-derived growth factor subunit B;
SCF, stem cell factor; sFas, soluble Fas cell surface death receptor;
TNF-a, tumor necrosis factor alpha.
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the CXCL12 receptor CXCR4.31,32 We observed signifi-
cantly increased concentrations of CXCL12 in serum of
cats with acute FIC. Studies investigating the role of
this chemokine in cystopathies of humans or cats have
not been reported. However, increased concentrations
of bladder tissue CXCL12 were documented in a
cyclophosphamide-induced bladder inflammation rat
model.33 Pain is one of the elements of both FIC and
IC/PBS, and the chemokine CXCL12 has been shown
to directly affect nociceptive neurons and induce pain.34
Another significantly increased cytokine in the serum
of FIC cats was Flt3L. The receptor for this ligand
(Flt3) is expressed in hematopoietic progenitor cells and
is crucial for development of dendritic cells and
enhances production of lymphoid progenitors.35–37
Flt3L has been implicated as a pro-inflammatory factor
in the pathogenesis of a variety of inflammatory
diseases.38–40 It also has been shown to have a protec-
tive, anti-inflammatory role in some animal models.39
One proposed mechanism for this action of Flt3L has
been the induction of T regulatory cells.41 The reason
for increased Flt3L in our cohort of FIC-affected cats is
unknown. To our knowledge, studies investigating the
role Flt3L in humans with IC/PBS have not been
reported. One could speculate that the reason for
increased serum Flt3L concentration is in response to
infection, whereas previously it has been noted that
Flt3L is transiently induced upon murine cytomegalo-
virus infection or exposure to toll-like receptor ago-
nists.42 The potential role of viral infection in the
pathogenesis of FIC has been previously investigated.43
Caliciviruses,44 feline foamy viruses,45,46 and gamma
herpesviruses47 have been proposed to be potential cau-
sative agents for FIC, but their role in pathogenesis is
unclear and needs further investigation.43,48 Flt3L also
can be produced by a wide variety of cells in the body
including both immune cells as well as nonimmune cells
such as fibroblasts or endothelial cells,49 and NK cells
are the major source of Flt3L in the body.50
We have identified several potential biomarkers of
acute FIC in serum of affected cats. However, our study
has limitations including relatively small sample size,
lack of samples from cats with chronic FIC and lack of
histologic phenotyping by light microscopy, and the ret-
rospective nature of the study. In addition, future stud-
ies incorporating additional control populations of cats
with non-FIC lower urinary tract diseases (eg, urolithia-
sis, bacterial urinary tract infection) as well as nonblad-
der diseases to assess the specificity of changes in
cytokine and chemokine concentrations are needed. The
limited number of patients decreased the statistical
power to detect more subtle differences in cytokine con-
centration and increased the risk of type II statistical
error in our data set, which raises the question of
whether the significant differences in cytokines observed
in the present study would be similar in a larger cohort
that included chronic cases. This limitation emphasizes
the need for future studies analyzing cytokines in
cohorts of patients with chronic FIC, because these cats
would especially benefit from sensitive and specific
biomarkers to measure treatment responses. Cases of
FIC in general and of chronic FIC in particular would
benefit from thorough phenotyping including cys-
toscopy and bladder biopsies to be able to fully assess
the diagnostic utility of cytokines in these cases.
Another potential limitation of our study may be rela-
tively low recovery of the multiplex assay and its ability
to identify more subtle differences in analytes with lower
Fig 1. Concentrations of IL-12(p40) (A), SDF1 (B), Flt3L (C), and IL-18 (D) in serum of 12 acute FIC cats were significantly higher than
in 13 healthy control cats. Graph presents median with 95% confidence interval.
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serum concentrations.17 Whereas concentrations of all
of the cytokines found to be significantly increased in
serum of FIC cats (IL-12 p40, SDF1, Flt3L, and IL-18)
were relatively high and well above the lower limits of
detection, it is conceivable that concentrations of other
cytokines could have been significantly different between
groups, but remained undetected because of poor ana-
lyte detection at low concentrations.
Another potential limitation is that in some of the
affected animals, slight increases in CK, AST, and ALT
enzyme activities were detected. Although the changes
were minimal and most likely not clinically relevant, we
cannot completely exclude that these findings may be
secondary to another ongoing disease process, which
could cause increases in serum cytokine concentrations.
The increase in CK activity was identified in the major-
ity of cats, but none of the animals was symptomatic
for myositis, and the increases probably were related to
muscle damage secondary to restraint, intramuscular
injection of sedatives or venipuncture. None of the ani-
mals developed any signs of muscular disease during
months of close monitoring during the clinical trial.
Increases in ALT (1/12) and AST (2/12) activities were
minimal and slightly above the reference range. None
of the cats had any changes identified on abdominal
ultrasound examination that were suggestive of ongoing
hepatic disease, such as cholangiohepatitis. The
increases could have been a result of in vitro hemolysis
after blood sampling.
Simultaneous determinations of serum and urine con-
centrations of cytokines and chemokines in affected and
healthy cats would have been of value in differentiating
local versus systemic responses. However, the optimal
methods for preparation and storage of feline urine
specimens for detection of urine cytokines have not
been determined. In addition, studies investigating the
analytical performance of the feline-specific multiplex
assay for detection of cytokines and chemokines in cat
urine have not been reported, but are being investigated
in our laboratory.
Ours is the first study investigating serum cytokine
concentrations in cats with FIC. We have identified sev-
eral cytokines that are increased in the serum cats with
FIC, which points to a pro-inflammatory milieu. Our
study creates a foundation for future studies investigat-
ing the role of cytokines in FIC and their utilization as
noninvasive biomarkers for diagnosis, differentiating
disease phenotypes, and monitoring therapeutic out-
comes in different forms of the disease. Future studies
are needed to optimize sample preparation and storage,
and to evaluate the specificity, sensitivity and clinical
utility of these serum and urine cytokines as noninva-
sive biomarkers for FIC.
Footnotes
a Milliplex MAP Feline Cytokine/Chemokine Magnetic Bead
Panel; Millipore, Billerica, MA
b Luminex 100; Luminex Corporation, Madison, WI
c Bio-Plex Manager 4.1.1; Bio-Rad, Hercules, CA
d GraphPad Prism 7.0; GraphPad, La Jolla, CA
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